SidaGhanaV1, PascalFrancis, Checkpoint, bibRecord, 000015

Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana

Identifieur interne : 000015 ( PascalFrancis/Checkpoint ); précédent : 000014; suivant : 000016

Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana

Auteurs : Kwamena William Coleman Sagoe [Ghana] ; Afrakoma Adjoa Agyei [Ghana] ; Francesca Ziga [Ghana] ; Margaret Lartey [Ghana] ; Theophilus K. Adiku [Ghana] ; Makafui Seshi Max Q. Arens [États-Unis] ; Julius Abraham Addo Mingle [Ghana]

Source :

Journal of medical virology [ 0146-6615 ] ; 2012.

RBID : Pascal:12-0195630

Descripteurs français

Pascal (Inist)
- Virus hépatite C, Virus hépatite B, Virus immunodéficience humaine, Prévalence, Epidémiologie, Antiviral, Antirétroviral, Traitement, Charge virale, Hépatite, Infection mixte, SIDA, Antigène CD4.

English descriptors

KwdEn :
- AIDS, Antiretroviral agent, Antiviral, Epidemiology, Hepatitis, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Mixed infection, Prevalence, Treatment, Viral load.

Abstract

Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4⁺ undertaken within 1 month (n = 83), CD4⁺ count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4⁺ counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4⁺ count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4⁺ and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000019
to stream PascalFrancis, to step Curation: 000110

Links to Exploration step

Pascal:12-0195630

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</title>
<author><name sortKey="Coleman Sagoe, Kwamena William" sort="Coleman Sagoe, Kwamena William" uniqKey="Coleman Sagoe K" first="Kwamena William" last="Coleman Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Adjoa Agyei, Afrakoma" sort="Adjoa Agyei, Afrakoma" uniqKey="Adjoa Agyei A" first="Afrakoma" last="Adjoa Agyei">Afrakoma Adjoa Agyei</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arens, Makafui Seshi Max Q" sort="Arens, Makafui Seshi Max Q" uniqKey="Arens M" first="Makafui Seshi Max Q." last="Arens">Makafui Seshi Max Q. Arens</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Addo Mingle, Julius Abraham" sort="Addo Mingle, Julius Abraham" uniqKey="Addo Mingle J" first="Julius Abraham" last="Addo Mingle">Julius Abraham Addo Mingle</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0195630</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0195630 INIST</idno>
<idno type="RBID">Pascal:12-0195630</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000019</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000110</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000015</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000015</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</title>
<author><name sortKey="Coleman Sagoe, Kwamena William" sort="Coleman Sagoe, Kwamena William" uniqKey="Coleman Sagoe K" first="Kwamena William" last="Coleman Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Adjoa Agyei, Afrakoma" sort="Adjoa Agyei, Afrakoma" uniqKey="Adjoa Agyei A" first="Afrakoma" last="Adjoa Agyei">Afrakoma Adjoa Agyei</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arens, Makafui Seshi Max Q" sort="Arens, Makafui Seshi Max Q" uniqKey="Arens M" first="Makafui Seshi Max Q." last="Arens">Makafui Seshi Max Q. Arens</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Addo Mingle, Julius Abraham" sort="Addo Mingle, Julius Abraham" uniqKey="Addo Mingle J" first="Julius Abraham" last="Addo Mingle">Julius Abraham Addo Mingle</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Epidemiology</term>
<term>Hepatitis</term>
<term>Hepatitis B virus</term>
<term>Hepatitis C virus</term>
<term>Human immunodeficiency virus</term>
<term>Mixed infection</term>
<term>Prevalence</term>
<term>Treatment</term>
<term>Viral load</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus hépatite C</term>
<term>Virus hépatite B</term>
<term>Virus immunodéficience humaine</term>
<term>Prévalence</term>
<term>Epidémiologie</term>
<term>Antiviral</term>
<term>Antirétroviral</term>
<term>Traitement</term>
<term>Charge virale</term>
<term>Hépatite</term>
<term>Infection mixte</term>
<term>SIDA</term>
<term>Antigène CD4</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4<sup>+</sup>
 undertaken within 1 month (n = 83), CD4<sup>+</sup>
 count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4<sup>+</sup>
 counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4<sup>+</sup>
 count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4<sup>+</sup>
 and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>84</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>COLEMAN SAGOE (Kwamena William)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ADJOA AGYEI (Afrakoma)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZIGA (Francesca)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LARTEY (Margaret)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ADIKU (Theophilus K.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ARENS (Makafui Seshi/ Max Q.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ADDO MINGLE (Julius Abraham)</s1>
</fA11>
<fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>6-10</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000509832130020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0195630</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4<sup>+</sup>
 undertaken within 1 month (n = 83), CD4<sup>+</sup>
 count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4<sup>+</sup>
 counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4<sup>+</sup>
 count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4<sup>+</sup>
 and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus hépatite C</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hepatitis C virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hepatitis C virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus hépatite B</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antirétroviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiretroviral agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiretroviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Charge virale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Viral load</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Carga vírica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hépatite</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Hepatitis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hepatitis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Infection mixte</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Mixed infection</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Infección mixta</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>SIDA</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>AIDS</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>SIDA</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Antigène CD4</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunodéficit</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immune deficiency</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunodeficiencia</s0>
<s5>13</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>17</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>17</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>17</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>18</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>18</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>18</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>19</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>19</s5>
</fC07>
<fN21><s1>149</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Ghana</li>
<li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
<li>Région du Grand Accra</li>
</region>
<settlement><li>Accra</li>
<li>Legon (Ghana)</li>
</settlement>
<orgName><li>Université du Ghana</li>
</orgName>
</list>
<tree><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Coleman Sagoe, Kwamena William" sort="Coleman Sagoe, Kwamena William" uniqKey="Coleman Sagoe K" first="Kwamena William" last="Coleman Sagoe">Kwamena William Coleman Sagoe</name>
</region>
<name sortKey="Addo Mingle, Julius Abraham" sort="Addo Mingle, Julius Abraham" uniqKey="Addo Mingle J" first="Julius Abraham" last="Addo Mingle">Julius Abraham Addo Mingle</name>
<name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name>
<name sortKey="Adjoa Agyei, Afrakoma" sort="Adjoa Agyei, Afrakoma" uniqKey="Adjoa Agyei A" first="Afrakoma" last="Adjoa Agyei">Afrakoma Adjoa Agyei</name>
<name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
</country>
<country name="États-Unis"><region name="Missouri (État)"><name sortKey="Arens, Makafui Seshi Max Q" sort="Arens, Makafui Seshi Max Q" uniqKey="Arens M" first="Makafui Seshi Max Q." last="Arens">Makafui Seshi Max Q. Arens</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000015 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000015 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:12-0195630
   |texte=   Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana

Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri